-
Abstract: The IN antigen is an antigen of the erythrocyte system,which has six antigens confirmed at present.Seventeen new exons were identified.The gene encoding product was adhesion molecule glycoprotein 44 and membrane differentiation antigen CD44.It can cause transfusion hemolysis and is an antigen of clinical significance.In antigen is one of the components of cytoskeleton protein,which participates in the formation of pseudopodia and cell migration.It has the function of adhesion of immune cells to tumor cells and is related to tumor metastasis.
-
Key words:
- IN antigen /
- 17 exons /
- adhesion molecule glycoprotein 44 /
- transfusion reaction
-
-
[1] Gogri H,Pitale P,Madkaikar M,et al.Molecular genotyping of Indian blood group system antigens in Indian blood donors[J].Transfus Apher Sci,201857:388-390.
[2] Joshi SR,Sheladiya A,Mendapara-Dobariya KV,et al.INRA,a new high-frequency antigen in the INDIAN(IN023)blood group system[J].Asian J Transfus Sci,2017,11:121-123.
[3] Geoff Daniels.Human Blood Groups[M].3rd.edition,2013:449-456.
[4] Marion E.Reid.The Blood Group Antigen[M].FactsBook,2012:567-576.
[5] Yang B,Dai JX,Pan YB,et al.Identification of biomarkers and construction of a microRNA-mRNA regulatory network for ependymoma using integrated bioinformatics analysis[J].Oncol Lett,2019,18:6079-6089.
[6] Lopez GH,Mcbean RS,Wilson B,et al.Molecular typing for the Indian blood group associated 252G＞C single nucleotide polymorphism in a selected cohort of Australian blood donors[J].Blood Transfus,2015,13:78-85.
[7] Ghoshal S,Gajendra P,Datta Kanjilal S,et al.Diversity analysis of MSP1 identifies conserved epitope organization in block 2 amidst high sequence variability in Indian Plasmodium falciparum isolates[J].Malar J,2018,17:447.
[8] Geng B,Pan J,Zhao T,et al.Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer[J].J Exp Clin Cancer Res,2018,30,37:208.
[9] Nakano M,Ito M,Tanaka R,et al.Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer[J].Cancer Sci,2018,109:3461-3470.
[10] Monroy EAC,de Andrade Santos PP,de Sousa Lopes MLD,et al.Oct-4 and CD44 in epithelial stem cells like of benign odontogenic lesions[J].Histochem Cell Biol,2018,150:371-377.
[11] Kim CK,Oh S,Kim SJ,et al.Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma[J].Genes Genomics,2018,40:381-388.
[12] Kim GH,Won JE,Byeon Y,et al.Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer[J].Drug Deliv,2018,25:1394-1402.
[13] Bitaraf SM,Mahmoudian RA,Abbaszadegan M,et al.Association of Two CD44 Polymorphisms with Clinical Outcomes of Gastric Cancer Patients[J].Asian Pac J Cancer Prev,2018,19:1313-1318.
[14] Lin X,You X,Cao X,et al.Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women[J].Med Sci Monit,2018,24:3077-3083.
[15] Ryoo IG,Choi BH,Ku SK,et al.High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells:Implications for cancer stem cell resistance[J].Redox Biol,2018,17:246-258.
[16] Liu Y,Wu T,Lu D,et al.CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer[J].Int J Biol Markers,2018,33:308-313.
[17] Hirth CG,Dos Santos AM,de Cerqueira JBG,et al.PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma[J].Biomed Res Int,2018,2018:2061268.
[18] Fan Z,Xia H,Xu H,et al.Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma[J].Biomed Pharmacother,2018,103:147-156.
[19] Tongtawee T,Wattanawongdon W,Simawaranon T,et al.Expression of Cancer Stem Cell Marker CD44 and Its Polymorphisms in Patients with Chronic Gastritis,Precancerous Gastric Lesion,and Gastric Cancer:A Cross-Sectional Multicenter Study in Thailand[J].Biomed Res Int,2017,2017:4384823.
[20] Hagiwara M,Kikuchi E,Tanaka N,et al.Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer[J].BMC Cancer,2018,18:113.
[21] Hou H,Ge C,Sun H,et al.Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44 s and the ERK1/2 pathway[J].Cancer Sci,2018,109:1088-1100.
[22] Matuura H,Miyamoto M,Takano M,et al.Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma[J].Anticancer Res,2018,38:717-722.
[23] Timirci-Kahraman Ö,Verim A,Verim A,et al.Expression of miR-373 and its predicted target genes E-cadherin and CD44 in patients with laryngeal squamous cell carcinoma[J].Cell Mol Biol(Noisy-le-grand),2017,63:29-33.,
[24] 李树中,卞洁,徐姿,等.Junier血型系统[J].临床血液学杂志,2014,27(10):913-915.
[25] 卞洁,李树中,李凌波,等.一个新的血型抗原—Langereis[J].临床血液学杂志,2015,28(12):1096-1100.
[26] 徐姿,李树中,卞洁,等.红细胞血型抗原的研究进展[J].临床血液学杂志,2016,29(4):345-350.
[27] 刘芸,李树中,李中华,等.多凝集红细胞的研究进展[J].临床血液学杂志,2016,29(6):215-217.
[28] 方莹,李树中,李凌波,等.forssman血型系统[J].临床血液学杂志,2016,29(2):171-174.
[29] 张志琴,李树中,谢怡萍,等.Duffy血型系统抗原研究进展[J].临床血液学杂志,2017,30(4):327-330.
[30] 倪强,李树中.GIL抗原研究进展[J].临床血液学杂志,2017,30(10):812-814.
[31] 俞黎娅,陆敏,李树中,等.VEL血型抗原研究进展[J].临床血液学杂志,2018,31(2):161-163.
[32] 刘芸,李树中,雒晶晶,等.AUG血型抗原研究进展[J].临床血液学杂志,2018,31(6):485-490.
[33] 范春丽,李树中,李中华,等.P1PK血型抗原研究进展[J].临床血液学杂志,2018,31(8):643-648.
[34] 张志琴,李树中,李中华,等.Duffy血型抗原的G-蛋白偶联受体作用[J].临床血液学杂志,2019,32(2):162-166.
[35] 王鹤,李树中,李中华,等.RHAG血型抗原研究进展[J].临床血液学杂志,2019,32(6):479-482.
[36] 叶小英,李树中,李中华,等.CD59-血型抗原的研究新进展[J].临床血液学杂志,2019,32(6):487-489.
-
计量
- 文章访问数: 181
- PDF下载数: 86
- 施引文献: 0
下载: